Matrix Laboratories, which was acquired by US generic drugmaker Mylan in 2007, is exploring new partnerships in India to launch about 100 products in the next 12 months - from anti-retroviral drugs to pain management and women's healthcare.
"We are open to small acquisitions as well. Our partner should have a brand and a sizeable portfolio of products but would be unable to fully leverage on it. The plan is still on the drawing board," said Rajiv Malik, Mylan's executive vice-president and chief executive officer. However, the launch of the products does not depend on the partnership, he said.
End-use drugs is a new territory for Matrix. Prior to being acquired by Mylan, Matrix was an active pharmaceutical ingredient ( API) manufacturer and was catering to a large base of other generic players in the US.
After it was acquired, it became the manufacturer of APIs in terms of drug master files filings. The $1-billion buyout was the largest deal in the pharmaceutical space.
For Mylan, Matrix worked as an entry window in fast-growing emerging pharmaceutical markets like India, China and Africa, where Matrix already had a significant presence through its various strategic alliances Since the acquisition, Matrix was serving emerging markets by expanding capacities in India. Currently, Matrix is short-listing drugs that would comprise its launch portfolio. "The products will be launched in phases. We are identifying (therapeutic) areas that are less crowded and offer a lot of growth.
That said, we certainly cannot leave out other highgrowth areas like blood pressure, oncology and diabetics," said Dr Hari Babu, acting chief executive officer and chief operating officer of Matrix Laboratories. Anti-retro viral (ARV) drugs, used to treat advanced stages of HIV/AIDS cases, will dominate the portfolio of drugs to be launched in Phase I as Matrix has more than 30 of these products commercialised in markets abroad. Some of Mylan's prescription drugs will also be in the list.
"We are open to small acquisitions as well. Our partner should have a brand and a sizeable portfolio of products but would be unable to fully leverage on it. The plan is still on the drawing board," said Rajiv Malik, Mylan's executive vice-president and chief executive officer. However, the launch of the products does not depend on the partnership, he said.
End-use drugs is a new territory for Matrix. Prior to being acquired by Mylan, Matrix was an active pharmaceutical ingredient ( API) manufacturer and was catering to a large base of other generic players in the US.
After it was acquired, it became the manufacturer of APIs in terms of drug master files filings. The $1-billion buyout was the largest deal in the pharmaceutical space.
For Mylan, Matrix worked as an entry window in fast-growing emerging pharmaceutical markets like India, China and Africa, where Matrix already had a significant presence through its various strategic alliances Since the acquisition, Matrix was serving emerging markets by expanding capacities in India. Currently, Matrix is short-listing drugs that would comprise its launch portfolio. "The products will be launched in phases. We are identifying (therapeutic) areas that are less crowded and offer a lot of growth.
That said, we certainly cannot leave out other highgrowth areas like blood pressure, oncology and diabetics," said Dr Hari Babu, acting chief executive officer and chief operating officer of Matrix Laboratories. Anti-retro viral (ARV) drugs, used to treat advanced stages of HIV/AIDS cases, will dominate the portfolio of drugs to be launched in Phase I as Matrix has more than 30 of these products commercialised in markets abroad. Some of Mylan's prescription drugs will also be in the list.
No comments:
Post a Comment